PT  - JOURNAL ARTICLE
AU  - Li, Ho Kwong
AU  - Zhu, Nina
AU  - Waddell, Olivia
AU  - Coelho, Juliana
AU  - Daniel, Roger
AU  - Guy, Rebecca L
AU  - Lamagni, Theresa
AU  - Sriskandan, Shiranee
TI  - Mortality among patients with invasive group A streptococcal infections caused by the M1<sub>UK</sub> lineage: a retrospective cohort study in England and Wales
AID  - 10.1101/2025.06.25.25330084
DP  - 2025 Jan 01
TA  - medRxiv
PG  - 2025.06.25.25330084
4099  - http://medrxiv.org/content/early/2025/06/27/2025.06.25.25330084.short
4100  - http://medrxiv.org/content/early/2025/06/27/2025.06.25.25330084.full
AB  - Background The M1UK sublineage of S. pyogenes has dominated post-pandemic upsurges in invasive group A streptococcal (iGAS) disease. Using a national cohort of patients with emm1 iGAS infections, we compared the case fatality rate (CFR) attributable to M1UK with ancestral emm1 lineages.Methods We linked emm1 S. pyogenes iGAS cases in England and Wales between December 2009-July 2022 to demographic and mortality data. We assigned lineage to isolates from 2010, 2013-2016, and 2020 using genome-sequencing or allele-specific PCR. Seven and 30-day all-cause CFR were determined for the entire cohort. Univariate and multivariate analyses were conducted to determine if lineage affected risk of death.Results In total, 4,952 emm1 iGAS cases were linked with demographic and mortality data; lineage was assigned to 1,356 cases. M1UK was associated with a 30-day CFR of 24.4%, compared with 22.3% for M1global, 10.5% for M123SNP, and 10.3% for M113SNP. After adjustment for age and sex, emm1 lineage was not a significant risk factor for death within 7 or 30 days. Survival analysis highlighted rapid time to death as a feature of both M1UK and M1global. Most deaths (63.7%) occurred within 1d of diagnostic sampling. Of children under 15 who died, 56.3% died before any sampling, and 95.6% died within 1d of sampling.Conclusions Significant differences in mortality were not identified between M1UK and M1global but larger studies are required. Mortality due to emm1 S. pyogenes is exceptionally high. Rapid time to death has implications for clinical trials: to impact death, interventions are required prior to culture-based diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the UK Medical Research Council (grant number MR/P022669/1 (SS), a Medical Research Council CMBI Clinical Research Training Fellowship (HKL), and the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Healthcare Associated Infections (HCAI) and Antimicrobial Resistance (AMR) at Imperial College London in partnership with the UK Health Security Agency, in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick [grant number NIHR200876]. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, the DHSC, or the UKHSA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The datasets used were individual-level data but fully de-identified prior to its use in this study. UK Health Security Agency surveillance of infections for health protection purposes is approved under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2020 and under Section 251 of the NHS Act 2006. The UKHSA Caldicott Advisory Panel gave approval for this work (CAP-2018-103 0008)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll de-identified data produced in the present study are available upon reasonable request to the authors